Biotransformation of two β-secretase inhibitors including ring opening and contraction of a pyrimidine rings

Drug Metabolism and Disposition

Volumn 41, Issue 5, 2013, Pages 1134-1147

  Lindgren, Anders ^a   Eklund, Göran ^a,d   Ture, Dominika ^b   Malmquist, Jonas ^d   Swahn, Britt Marie ^b   Holenz, Jörg ^b   Berg, Stefan Von ^b,c   Karlström, Sofia ^b   Bueters, Tjerk ^a  

^a Drug Metabolism and Pharmacokinetics   (Sweden)

^b Department of Neuroscience AstraZeneca R and D   (Sweden)

^c Medicinal Chemistry   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (DIFLUOROMETHYL)PYRIDIN 4 YL] 4 FLUORO 1 [3 (PYRIMIDIN 5 YL)PHENYL] 1H ISOINDOL 3 AMINE HEMIFUMARATE; 1 PYRIDIN 4 YL 4 FLUORO 1 [3(PYRIMIDIN 5 YL)PHENYL] 1H ISOINDOL 3 AMINE; 4 PYRIMIDONE; AZD 3839; BETA SECRETASE INHIBITOR; CYTOCHROME P450 3A4; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE 2,4 DIONE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG URINE LEVEL; HUMAN; IN VITRO STUDY; ISOTOPE LABELING; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RABBIT; RAT; STRUCTURE ANALYSIS;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; CYCLIZATION; ENZYME INHIBITORS; HUMANS; INDOLES; MALE; MASS SPECTROMETRY; PYRIMIDINES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY;

ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 84876750749     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050351     Document Type: Article

References (32)

1. Aasa J, Hu Y, Eklund G, Lindgren A, Baranczewski P, Malmquist J, Turek D, and Bueters T (2013) Effect of solvents on the time-dependent inhibition of CYP3A4 and the biotransformation of AZD3839 in human liver microsomes and hepatocytes. Drug Metab Dispos 41:159-169.
2. Axelsson H, Granhall C, Floby E, Jaksch Y, Svedling M, and Sohlenius-Sternbeck A-K (2003) Rates of metabolism of chlorzoxazone, dextromethorphan, 7-ethoxycoumarin, imipramine, quinidine, testosterone and verapamil by fresh and cryopreserved rat liver slices, and some comparisons with microsomes. Toxicol In Vitro 17:481-488.
3. Cumming JN, Smith EM, Wang L, Misiaszek J, Durkin J, Pan J, Iserloh U, Wu Y, Zhu Z, and Strickland C, et al. (2012) Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor. Bioorg Med Chem Lett 22:2444-2449.
4. Floby E, Johansson J, Hoogstraate J, Hewitt NJ, Hill J, and Sohlenius-Sternbeck A-K (2009) Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes. Xenobiotica 39:656-662.
5. Forman M, Palcza J, Tseng J, Leempoels J, Ramael S, Han D, Jhee S, Ereshefsky L, Tanen M, and Laterza O, et al. (2012) The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Ab peptides in healthy subjects following single-and multiple-dose administration. Alzheimers Dement 8:704.
6. Fukiya K, Itoh K, Yamaguchi S, Kishiba A, Adachi M, Watanabe N, and Tanaka Y (2010) A single amino acid substitution confers high cinchonidine oxidation activity comparable with that of rabbit to monkey aldehyde oxidase 1. Drug Metab Dispos 38:302-307.
7. Garattini E, Fratelli M, and Terao M (2008) Mammalian aldehyde oxidases: Genetics, evolution and biochemistry. Cell Mol Life Sci 65:1019-1048.
8. Garattini E and Terao M (2012) The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8:487-503.
9. Ghosal A, Ramanathan R, Yuan Y, Hapangama N, Chowdhury SK, Kishnani NS, and Alton KB (2007) Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Drug Metab Dispos 35:2186-2195.
10. Gravenfors Y, Viklund J, Blid J, Ginman T, Karlström S, Kihlström J, Kolmodin K, Lindström J, von Berg S, and von Kieseritzky F, et al. (2012) New aminoimidazoles as b-secretase (BACE-1) inhibitors showing amyloid-b (Ab) lowering in brain. J Med Chem 55:9297-9311.
11. Hardy J and Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12:383-388.
12. Hardy J and Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356.
13. Huskey SW, Doss GA, Miller RR, Schoen WR, and Chiu SH (1994) N-glucuronidation reactions. II. Relative N-glucuronidation reactivity of methylbiphenyl tetrazole, methylbiphenyl triazole, and methylbiphenyl imidazole in rat, monkey, and human hepatic microsomes. Drug Metab Dispos 22:651-658.
14. Jeppsson F, Eketjäll S, Janson J, Karlström S, Gustavsson S, Olsson LL, Radesäter AC, Ploeger B, Cebers G, and Kolmodin K, et al. (2012) Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem 287: 41245-41257.
15. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, and Ames MM (2002) Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 62:143-153.
16. Lai R, Albala B, Kaplow JM, Aluri J, Yen M, and Satlin A (2012) First in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma b amyloid levels after single dosing. Alzheimers Dement 8:96.
17. Lee VMY, Goedert M, and Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121-1159.
18. Lu Y, Riddell D, Hajos-Korcsok E, Bales K, Wood KM, Nolan CE, Robshaw AE, Zhang L, Leung L, and Becker SL, et al. (2012a) Cerebrospinal fluid amyloid-b (Ab) as an effect biomarker for brain Ab lowering verified by quantitative preclinical analyses. J Pharmacol Exp Ther 342:366-375.
19. Lu Y, Barton HA, Leung L, Zhang L, Hajos-Korcsok E, Nolan CE, Liu J, Becker SL, Wood KM, and Robshaw AE, et al. (2012b) Cerebrospinal fluid b-amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses. Neurodegener Dis [Epub ahead of print].
20. Nelson CC and McCloskey JA (1994) Collision-Induced Dissociation of Uracil and Its Derivatives. J Am Soc Mass Spectrom 5:339-349.
21. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, and Watson BM, et al. (2011) Robust central reduction of amyloid-b in humans with an orally available, non-peptidic b-secretase inhibitor. J Neurosci 31:16507-16516.
22. Morrison RD, Blobaum AL, Byers FW, Santomango TS, Bridges TM, Stec D, Brewer KA, Sanchez-Ponce R, Corlew MM, and Rush R, et al. (2012) The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5. Drug Metab Dispos 40:1834-1845.
23. Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, and Gregro AR, et al. (2009) First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther 328: 131-140.
24. Sridhar L, Karthikraj R, Murty MR, Raju NP, Vairamani M, and Prabhakar S (2011) Mass spectral analysis of N-oxides of Chemical Weapons Convention related aminoethanols under electrospray ionization conditions. Rapid Commun Mass Spectrom 25:533-542.
25. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, and Hong J, et al. (1999) Purification and cloning of amyloid precursor protein betasecretase from human brain. Nature 402:537-540.
26. Sohlenius-Sternbeck A-K, Afzelius L, Prusis P, Neelissen J, Hoogstraate J, Johansson J, Floby E, Bengtsson A, Gissberg O, and Sternbeck J, et al. (2010) Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40:637-649.
27. Swahn BM, Holenz J, Kihlström J, Kolmodin K, Lindström J, Plobeck N, Rotticci D, Sehgelmeble F, Sundström M, and Berg Sv, et al. (2012a) Aminoimidazoles as BACE-1 inhibitors: The challenge to achieve in vivo brain efficacy. Bioorg Med Chem Lett 22: 1854-1859.
28. Swahn BM, Kolmodin K, Karlström S, von Berg S, Söderman P, Holenz J, Berg S, Lindström J, Sundström M, and Turek D, et al. (2012b) Design and synthesis of b-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of b-amyloid peptides. J Med Chem 55:9346-9361.
29. Truong AP, Tóth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, and Sham HL, et al. (2010) Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett 20:6231-6236.
30. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, and Loeloff R, et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735-741.
31. Weiss MM, Williamson T, Babu-Khan S, Bartberger MD, Brown J, Chen K, Cheng Y, Citron M, Croghan MD, and Dineen TA, et al. (2012) Design and preparation of a potent series of hydroxyethylamine containing b-secretase inhibitors that demonstrate robust reduction of central b-amyloid. J Med Chem 55:9009-9024.
32. Wood S, Wen PH, Zhang J, Zhu L, Luo Y, Babu-Khan S, Chen K, Pham R, Esmay J, and Dineen TA, et al. (2012) Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived b-secretase inhibitors. J Pharmacol Exp Ther 343:460-467.